Experimental Pill ERAS-0015 Shrinks Tumours in Nearly Half of Early Pancreatic Cancer Trial Patients, Canadian Oncologist Says

pancreatic cancer drug trial: An experimental pill, ERAS-0015, shrank tumours in 44 per cent of 25 patients with pancreatic cancer in an early-stage trial reported by San Diego drugmaker Erasca. Canadian oncologists call it a major advance, and a late-stage trial is planned for Canada in 2027.

pancreatic cancer drug trial, Digimart Global (Canada): An experimental U.S. drug is drawing attention from Canadian doctors after early clinical trial results reported positive effects in patients with advanced pancreatic and lung cancers.

The drugmaker Erasca, based in San Diego, Calif., reported the results on Friday.

Erasca said 44 per cent of 25 patients with pancreatic cancer saw their tumours shrink substantially after taking a 32 mg daily dose of the pill, ERAS-0015. The company also said 69 per cent of patients with the two most common genetic variations of pancreatic cancer had positive results. In lung cancer, tumours diminished in three of five patients (60 per cent) who had previously received immunotherapy and chemotherapy.

Dr. Jennifer Knox, a staff medical oncologist at the University Health Network’s Princess Margaret Cancer Centre in Toronto, said the results are a significant development, calling them “the biggest breakthrough for pancreas cancer probably ever” in a phone interview with CTV News.

She noted that the trial was small, which she said is typical at this early phase, and she expects many people to take part when the global trial reaches Canada next year.

Erasca said it will begin late-stage clinical trials of ERAS-0015 and another experimental treatment, ERAS-4001, in 2027. Knox will supervise patients in the Canadian portion of the trial. She compared the drug with daraxonrasib, a related experimental medication from Revolution Medicines, which a U.S.-led study published in The New England Journal of Medicine in May said doubled patients’ survival time in a clinical trial.

Knox said daraxonrasib is now licensed in the U.S.

Erasca CEO Dr. Jonathan Lim said in a press release that the treatment was “generally well tolerated,” but the company had previously reported that one patient taking a 24 mg dose had died from lung inflammation.

Dr. Sam Godfrey of Cancer Research UK, speaking to CTV, was optimistic but cautioned that cancer may return and that longer trials are needed.

Doctors say RAS proteins act as on-off switches for cell growth and can drive cancer when mutated; the pill appears to block mutant RAS proteins that could allow cancer cells to multiply.

Leave a Reply

Your email address will not be published. Required fields are marked *

Sports

Explore Digimart Global